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AP = activator protein; EBS = Ets-binding site.
Available online http://breast-cancer-research.com/content/3/6/395
Introduction
Over-expression of ERBB2 (HER-2/neu) is an adverse
prognostic factor in human breast cancer, and may predict
resistance to both chemotherapy and endocrine therapy
(for review [1]). This over-expression was originally attrib-
uted solely to amplification of the ERBB2 gene (usually 2-
to 10-fold), which frequently occurs both in tumours and in
derived cell lines. It became clear, however, that over-
expression can also be observed from a single copy gene
[2]. Moreover, in all of the cell lines examined that exhibit
gene amplification, an elevation in ERBB2 mRNA levels
per gene copy was also observed [2]. This indicated that
over-expression of the gene precedes and increases the
likelihood of gene amplification, suggesting that further
research into the transcriptional regulation of ERBB2
would be informative.
Consequently, a number of groups have used nuclear run-
on assays to measure gene transcription rates, and these
have shown an increase in transcription rate sufficient to
account for the degree of over-expression in a number of
breast tumour derived cell lines that over-express ERBB2
(for review [3]). Subsequent studies therefore sought to
identify the gene sequences that are required to mediate
this increase in transcription rate. This was largely done by
examining the activity of reporter constructs that contain
the major transcription initiation site plus various extents of
the ERBB2 5′-flanking sequence, and hence comparing
promoter activity in breast tumour lines with low and high
levels of expression. The results of those experiments are
summarized here, and attempts either to target promoter
function or to exploit the differential activity of the ERBB2
promoter for use in genetic therapies are reviewed.
ERBB2 promoter structure and interacting
factors
The human ERBB2 proximal promoter contains typical
TATA and CCAAT boxes, at –22 to –26 bp and –71 to
–75 bp, respectively (Fig. 1); it should be noted that the
TATA box is not conserved in the rodent neu gene, making
it difficult to compare studies across species, and there-
fore only data from the human gene are discussed here.
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Two regions of transcription initiation have been mapped
within the ERBB2 promoter; one grouped around the
major start site at +1, with minor starts centred at –69
(Fig. 1). Transcription initiation at these two sites appears
to occur by two separate mechanisms, with the upstream
start site being specified by and dependent upon an initia-
tor-like element, whereas the downstream sites require the
presence of the TATA box. In over-expressing cells it is the
–69 initiation site that appears to be preferentially upregu-
lated (for review [3,4]). An additional feature of the
ERBB2 promoter is a 27 bp polypurine (GGA)/polypyrimi-
dine (TCC) mirror repeat at –40 to –66 (Fig. 1). This
sequence has been reported to overlap a putative matrix
attachment region within the promoter, and it has the
potential to form a distinct architectural conformation
known as Hr-DNA, which is an internal triplex structure
with a single-stranded D-loop [4].
ERBB2 promoter activity was initially demonstrated in
reporter assays using sequences from –500 to +40 [5,6].
Subsequently, a whole range of reporter constructs were
used by different laboratories containing up to 6.0 kb of
ERBB2 5′-flanking sequence (for review [3]). The majority
of those studies also compared reporter activity in breast
cell lines with either high or low expression of ERBB2.
Clear differential activity was observed, with sequences
up to –300 being able to mediate the majority of this
effect, whereas further 5′-flanking sequences had little
positive influence on promoter activity. These findings tally
well with separate studies mapping nuclear DNase I
hypersensitive sites, which often indicate regions of regu-
latory importance within a gene. One site was mapped
within the ERBB2 promoter, centred on the region of the
CAAT and TATA boxes, and extending both upstream and
downstream [7,8], although it is not possible to define the
precise limits. No other hypersensitive sites were detected
within 6 kb 5′ of +1, suggesting that much of this region
may be inaccessible to trans-acting factors in vivo and
that the only sequences of regulatory significance reside
within the proximal promoter. One additional hypersensi-
tive site upstream of –6.0 kb was observed [8]. Intrigu-
ingly, there has been a report that an additional ERBB2
promoter, associated with alternative 5′ exons, exists
12 kb upstream of the conventional start of the gene [9].
However, preliminary experiments in these laboratories
have indicated that, although the region probably contains
a functional promoter, it does not demonstrate differential
activity between cells with low and high expression of
ERBB2 (Brown N, unpublished data).
A number of transcription factors have been demonstrated
to bind to the ERBB2 proximal promoter (for review [3,4]).
However, only two of these, namely the AP-2 and Ets fami-
lies of transcription factors (Fig. 1), have been shown to
be both required for maximal promoter activity and associ-
ated with over-expression of the gene in breast cancer.
The AP-2 binding site (GCTGCAGGC) at –213 to –221
was originally identified as a DNase I footprinted site that
was protected by nuclear extracts from ERBB2 over-
expressing cells (but not those with low expression), indi-
cating differential DNA-binding activity of a nuclear factor,
which was termed OB2-1. Mutation of the site to prevent
binding resulted in impaired reporter activity in ERBB2
over-expressing cells [10]. OB2-1 was subsequently
shown to be the developmentally regulated transcription
factor AP-2 [11], which consists of a family of three highly
homologous proteins, AP-2α, AP-2β and AP-2γ, all of
which can activate the ERBB2 promoter [12]. Levels of
AP-2α and AP-2γ proteins have been shown to correlate
with ERBB2 over-expression in tumour derived cell lines
and primary breast tumours [12,13].
The Ets binding site (EBS; GAGGAA), at –33 to –28,
maps over a DNase I hypersensitivity site, the intensity of
which is more marked in footprinting assays that use
extracts from over-expressing cells [4,7]. Moreover, muta-
tion of this site also impaired reporter activity [4,7,14]. It
has been reported that binding of Ets factors to the EBS
induces a severe bend in the DNA [4]. It is therefore likely
that if the EBS is occupied then the TATA-binding protein
will not be able to access the closely associated TATA
box, making EBS binding an attractive explanation for the
increased use of the –69 start site that is observed in
over-expressing cells. At least 10 different Ets proteins
Figure 1
Features of the ERBB2 promoter. The ERBB2 promoter from –75 to +15 is represented approximately to scale, with an additional area depicting
sequences upstream of –200. The major (+1) and minor (–69) transcription start sites are indicated with arrows and the positions of the TATA and
CCAAT boxes are marked; the polypyrimidine/polypurine repeat is shown as an open box. The relative positions of the main transcription factor
binding sites AP-2, Ets and ZONAB are indicated, with the sequences below each giving the core binding site defined for each factor. Translation
of the protein begins at +178 relative to the major transcription start site.
-69 +1
ATTGG GCTGCAGGC GAGGAA
TATA CCAAT –217 –30 +13
Ets AP-2 ZONABc
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
have been found in breast cells at varying levels. Of those,
only PEA3 has so far been shown to correlate in distribu-
tion with ERBB2  over-expression [15], but there have
been conflicting reports as to whether this protein acti-
vates or represses the ERBB2 promoter [4,14].
Targeting ERBB2 promoter function
Although the precise molecular mechanisms that govern
ERBB2 promoter activity in over-expressing cells and in
those with low levels of expression are far from being
totally defined, a number of strategies have been explored
to limit promoter activity in over-expressing cells. The ratio-
nale is that it will be more efficient to reduce ERBB2 levels
by preventing the transcription of 2–10 gene copies than
trying to neutralize up to 106 receptor molecules com-
monly found in over-expressing cells. The main strategies
used to date fall into two groups: those targeting the AP-2
or EBS and those targeting the polypurine/polypyrimidine
repeat structure.
The AP-2 and Ets sites have been targeted by either pre-
venting the binding of the cognate binding protein (using
sodium aurothiomalate for AP-2 [16] and DNA-binding
polyamides for Ets factors [17]) or by creating fusion pro-
teins between the appropriate DNA-binding domain and a
transcriptional repressor [4], in all cases impairing pro-
moter activity in functional assays. These approaches have
only been used in vitro, but another strategy, based on the
observation that over-expression of the Ets factor PEA3
reduced ERBB2 expression, has also been examined in
preclinical trials. Breast and ovarian tumour lines with
either low expression or over-expression of ERBB2 were
grown as xenografts in nude mice and treated with daily
injections of liposome-conjugated PEA3 expression
plasmid. Significant reductions in tumour growth were
observed in the ERBB2 over-expressing lines, with some
mice surviving over a year, whereas growth of the tumours
with low expression was unaffected [14].
The polypurine/polypyrimidine repeat provides an interest-
ing target because of its ability to bind triplex-forming
oligonucleotides. A number of papers have described suc-
cessful triplex targeting, resulting in a reduction in Ets
factor binding at the adjacent EBS (for review see [4]).
Reduced promoter activity has also been reported in cells
transduced with a retrovirus expressing an antigene RNA
targeted to the same sequence [18]. Perhaps the most
novel approach, however, is the construction of six-fingered
zinc finger proteins designed to bind 18 bp of the poly-
purine/polypyrimidine repeat in a genome-specific manner.
Fusing a variety of repression domains to these synthetic
DNA-binding proteins resulted, in one case, in total abla-
tion of promoter activity in in vitro reporter assays [19].
None of the above strategies have yet proceeded to
patient trials, but another approach has now entered
clinical trials. Work on the rodent neu promoter revealed
that coexpression of certain tumour-related proteins,
namely adenovirus E1a, SV40 large T antigen, c-Myc or
the retinoblastoma gene product Rb, could apparently
downregulate promoter activity (for review [3]). The mech-
anism by which this occurs is unclear; it is certainly indi-
rect and may not actually be related to expression of
ERBB2 or  neu. Nevertheless, experiments in animal
models were promising enough to lead to a phase I trial in
which cationic lipids were used to transfer an E1a expres-
sion plasmid into ERBB2-positive breast and ovarian
tumour cells. The approach was found to be safe with no
dose-limiting toxicity and showed some antitumour effects,
notably increased apoptosis. A phase II trial in head and
neck cancer patients, however, indicated that E1a is effec-
tive irrespective of the ERBB2 status of the tumour [1].
Using differential ERBB2 promoter activity in
genetic prodrug-activation therapy
Genetic prodrug-activation therapy is designed to selec-
tively express a non-mammalian metabolic ‘suicide’ gene
in tumour cells such that a coadministered non-toxic
prodrug will be converted into its toxic metabolite only
within the tumour cells. In principle, this can be achieved
by using a differentially active promoter such as ERBB2 to
drive expression of the suicide gene. Preclinical trials
using the Escherichia coli cytosine deaminase gene,
which can convert 5-fluorocytosine to 5-fluorouracil,
showed that cell toxicity could be limited to ERBB2 over-
expressing cells using this strategy [20]. This led to a
phase I clinical trial in 12 patients with skin nodule metas-
tases of their primary breast tumours. The ERBB2/cyto-
sine deaminase expression plasmid was injected directly
into a nodule, with an adjacent nodule receiving a control
injection of vector DNA alone. The approach was shown
to be safe, and significant levels of suicide gene expres-
sion specifically restricted to the ERBB2 positive tumour
cells were observed, thus demonstrating the selectivity of
the approach [21].
Conclusion
Better delivery vehicles are required if advances in gene
therapy approaches are to continue. Adenoviral vectors, a
common choice for cancer gene therapy, were found to
suppress the differential activity of the ERBB2 promoter,
but this may be overcome by using genetic tricks such as
the use of so-called insulator elements [22]. In addition,
although the ERBB2 promoter is selectively active, it is
not very potent, and so combinations with additional regu-
latory elements either from other genes such as MUC1
[23] or potentially using recently discovered ERBB2
intronic enhancers [8] may be used to increase expression
of the delivered gene. The nature of this gene itself is open
to wide variation, and strategies to increase tumour cell
sensitivity to chemotherapy or radiotherapy by delivering
appropriate genes are also being investigated [24].
Available online http://breast-cancer-research.com/content/3/6/395In terms of transcriptional therapy, it is unlikely that sys-
temic drugs that are specific either for AP-2 or Ets factors
will be developed in the short term. Therefore, the strate-
gies that are most likely to enter the clinic are use of gene
therapy vectors to deliver transcriptional repressor mole-
cules to ERBB2 over-expressing cells. Possible candi-
dates include PEA3 [14], the synthetic polydactyl zinc
finger proteins [19], AP-2 or Ets-repressor fusion proteins
[4], or possibly a recently identified factor termed ZONAB.
This is Y-box transcription factor that binds a site just
downstream of +1 (Fig. 1) and represses ERBB2 pro-
moter activity in a cell-density-dependent manner [25].
These approaches also need further evaluation, however;
the relative potency of these different molecules must be
directly compared, followed by preclinical testing in order
to determine how safe and effective they may be in vivo.
An additional consideration is the likelihood of an immune
response, particularly to the synthetic molecules; this may
actually prove to be an advantage in tumour eradication,
although the lack of an immunocompetent model for
breast cancer may make this difficult to evaluate.
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